

## AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions and listings of claims in this application.

### Listing of the Claims:

1-20. (Canceled)

21. (Previously presented) An isolated antibody or fragment thereof that specifically binds a polypeptide consisting of SEQ ID NO:2.

22. (Canceled)

23. (Currently amended) The antibody or fragment thereof of claim 21, wherein the antibody is a monoclonal antibody.

24. (Currently amended) The antibody or fragment thereof of claim 21, wherein the fragment is an Fv, Fab, or Fab2 fragment.

25. (Currently amended) The antibody or fragment thereof of claim 21, wherein the antibody is a humanized antibody.

26. (Currently amended) The antibody or fragment thereof of claim 21, wherein the antibody is polyclonal.

27. (Currently amended) The antibody or fragment thereof of claim 21, wherein the antibody is a neutralizing antibody.

28-40. (Canceled)

41. (Currently amended) The antibody or fragment thereof of claim 21, wherein the antibody is a chimeric antibody.

42. (Currently amended) A hybridoma that is capable of producing comprising  
~~the~~ an antibody that specifically binds a polypeptide consisting of SEQ ID NO:2 of claim 21.

43. (Previously presented) A composition comprising the antibody or fragment thereof of claim 21.

44. (Previously presented) The composition of claim 43, wherein the composition is formulated for parenteral administration.